ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ALK Alkemy Capital Investments Plc

87.50
0.00 (0.00%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Alkemy Capital Investments Plc LSE:ALK London Ordinary Share GB00BMD6C023 ORD GBP0.02
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 87.50 85.00 90.00 87.50 87.50 87.50 19,817 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Offices-holdng Companies,nec 0 -2.65M -0.3239 -2.70 7.14M

0OIR Release Date Of Nine-month Interim Report (Q3) 2021 For Alk And Audio Cast

05/11/2021 10:22am

UK Regulatory


Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Alkemy Capital Investments Charts.
 
TIDMALK TIDMB 
 

On Thursday, 11 November 2021, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its nine-month interim report (Q3) 2021.

ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CET) at which Management will review the financial results, the outlook and answer questions.

The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins.

Participants in the conference call are kindly requested to call in before 1.25pm (CET). Danish participants should call in on tel. +45 3544 5577 and international participants should call in on tel. +44 333 300 0804 or +1 631 913 1422. Please use the following participant pin code: 25705608#

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, mobile +45 3050 2014

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,500 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

   -- InvestorNews_05Nov21 
      https://ml-eu.globenewswire.com/Resource/Download/1c047004-7a51-4f6c-8801-a979506d0157 
 
 
 

(END) Dow Jones Newswires

November 05, 2021 06:22 ET (10:22 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Alkemy Capital Investments Chart

1 Year Alkemy Capital Investments Chart

1 Month Alkemy Capital Investments Chart

1 Month Alkemy Capital Investments Chart

Your Recent History

Delayed Upgrade Clock